Literature DB >> 16360311

Randomised clinical trial comparing oral versus depot formulations of zuclopenthixol in patients with schizophrenia and previous violence.

C Arango1, I Bombín, T González-Salvador, I García-Cabeza, J Bobes.   

Abstract

PURPOSE: The aim of this longitudinal study was to determine whether the depot formulation of an antipsychotic reduces violence in outpatients with schizophrenia as compared to oral administration of the same antipsychotic.
METHODS: Forty-six previously violent patients with schizophrenia were randomised to receive treatment with oral or depot zuclopenthixol for 1 year. Clinicians interviewed patients at baseline and every month thereafter to assess treatment adherence. An interviewer blinded to treatment assignments interviewed an informant about any violent behaviour during the previous month.
RESULTS: Violence during the follow-up year was inversely proportional to treatment adherence, better compliance, and greater reduction of positive symptoms. Lower frequency of violent acts was observed in the depot group. The level of insight at baseline was not significantly associated with violence recidivism. Regardless of route of administration, treatment non-adherence was the best predictor of violence.
CONCLUSIONS: Some patients with schizophrenia and prior violent behaviour may benefit from the depot formulation of antipsychotic medication.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16360311     DOI: 10.1016/j.eurpsy.2005.07.006

Source DB:  PubMed          Journal:  Eur Psychiatry        ISSN: 0924-9338            Impact factor:   5.361


  16 in total

Review 1.  Correlates and long-term consequences of poor insight in patients with schizophrenia. A systematic review.

Authors:  Tania M Lincoln; Eva Lüllmann; Winfried Rief
Journal:  Schizophr Bull       Date:  2007-02-08       Impact factor: 9.306

2.  [Insight and Violent Behavior in a Cohort of Early Psychosis Patients].

Authors:  Valerie Moulin; Julie Palix; Luis Alameda; M Mehdi Gholamrezaee; Philipp S Baumann; Jacques Gasser; Julien Elowe; Alessandra Solida; Philippe Conus
Journal:  Can J Psychiatry       Date:  2017-06-28       Impact factor: 4.356

Review 3.  Zuclopenthixol dihydrochloride for schizophrenia.

Authors:  Edward J Bryan; Marie Ann Purcell; Ajit Kumar
Journal:  Cochrane Database Syst Rev       Date:  2017-11-16

Review 4.  Pharmacological management of acute and persistent aggression in forensic psychiatry settings.

Authors:  Leslie Citrome; Jan Volavka
Journal:  CNS Drugs       Date:  2011-12-01       Impact factor: 5.749

Review 5.  Defining and assessing adherence to oral antipsychotics: a review of the literature.

Authors:  Dawn I Velligan; Yui-Wing Francis Lam; David C Glahn; Jennifer A Barrett; Natalie J Maples; Larry Ereshefsky; Alexander L Miller
Journal:  Schizophr Bull       Date:  2006-05-17       Impact factor: 9.306

6.  The Potential Role of Long-acting Injectable Antipsychotics in People with Schizophrenia and Comorbid Substance Use.

Authors:  Maju Mathew Koola; Heidi J Wehring; Deanna L Kelly
Journal:  J Dual Diagn       Date:  2012

7.  Schizophrenia--time to commit to policy change.

Authors:  W Wolfgang Fleischhacker; Celso Arango; Paul Arteel; Thomas R E Barnes; William Carpenter; Ken Duckworth; Silvana Galderisi; Lisa Halpern; Martin Knapp; Stephen R Marder; Mary Moller; Norman Sartorius; Peter Woodruff
Journal:  Schizophr Bull       Date:  2014-04       Impact factor: 9.306

8.  Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials.

Authors:  Taishiro Kishimoto; Alfred Robenzadeh; Claudia Leucht; Stefan Leucht; Koichiro Watanabe; Masaru Mimura; Michael Borenstein; John M Kane; Christoph U Correll
Journal:  Schizophr Bull       Date:  2012-12-17       Impact factor: 9.306

Review 9.  From Clozapine to Cognitive Remediation.

Authors:  Jason Quinn; Nathan J Kolla
Journal:  Can J Psychiatry       Date:  2016-07-10       Impact factor: 4.356

10.  Medication and aggressiveness in real-world schizophrenia. Results from the FACE-SZ dataset.

Authors:  G Fond; L Boyer; M Favez; L Brunel; B Aouizerate; F Berna; D Capdevielle; I Chereau; J M Dorey; C Dubertret; C Faget; F Gabayet; H Laouamri; C Lancon; Y Le Strat; D Misdrahi; R Rey; C Passerieux; A Schandrin; F Schurhoff; A M Tronche; M Urbach; P Vidalhet; P M Llorca; A Pelissolo
Journal:  Psychopharmacology (Berl)       Date:  2015-12-03       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.